EZH2 and cancer: In multiple MLL1-rearranged leukaemia cells, 57 depleted EZH2, EED and SUZ12 and demonstrated the significant anti-tumour effect in a variety of cancer lines and patient-derived models as well as in multiple tumour cell line xenografted and PDX models.72